Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Pharmaceutical and Clinical Research

Vol. 6, Issue 2, Part B (2024)

Evaluation of PD-L1 protein expression in primary breast carcinoma: An immunohistochemical study

Author(s):

Dr. P Kanmani

Abstract:

Breast cancer is currently the leading cause of death among women in India with 25.8 per 100,000 women and mortality 12.7 per 100,000 women. In addition to surgery, conventional chemotherapy regimens, hormonal therapy and anti-HER 2 therapy (Herceptin) employed in some cases depending on biomarker results. In this aspect, the Programmed death (PD-1/PD-L1) pathway is of great interest. The activation of this pathway is found to be a poor prognostic factor in cancers of Lung, Gastrointestinal tract, Kidney. Therefore analysis of PD-L1 expression in breast cancer may help in clarifying the role of this pathway in tumor proliferation and may guide further research towards new treatment modalities. Currently anti-PD-L1 therapy useful in Non-small cell lung carcinoma, Urothelial malignancies, and Melanoma.Various papers published on this topic based on research in the western population. Molecular profile of breast cancer in the Indian scenario may be different from these results. Hence data from Indian patients is imperative to extrapolate the conclusions reached from studies in the western population.

Pages: 71-72  |  209 Views  73 Downloads


International Journal of Pharmaceutical and Clinical Research
How to cite this article:
Dr. P Kanmani. Evaluation of PD-L1 protein expression in primary breast carcinoma: An immunohistochemical study. Int. J. Pharm. Clin. Res. 2024;6(2):71-72. DOI: 10.33545/26647591.2024.v6.i2b.106
Call for book chapter